

Provider Bulletin

Reference: B1900437



All Providers

1	Did You Know? Process for Refunding Payments
1	Enrollment Application Date of Birth (DOB) Requirement Reminder
2	Updated Process for Member Date of Death Verification
-	Ophaletri i coession menteri Dale or Dealtry emicatori
	Clinics, Non-Physician Practitioner, Occupational
	Therapist, Rehabilitation Agencies
2	Non-Covered Modalities Under the Occupational Therapy
	Benefit
	Dental Providers
	Dental Ploviders
2	Child Health Plan Plus (CHP+) Prenatal Dental Benefit
	Home & Community-Based Service (HCBS) Providers
3	I hat I hat for Describer Onde T2007
3	Unit Limit Update for Procedure Code T2003
	HCBS, Home Health, Hospice, Private Duty Nursing,
	Outpatient Therapy, and DME Providers
3	Electronic Visit Verification (EVV) Training Announcement
	Hospice Providers
5	Hospice Facility Fiscal Year 2019-2020 Rate Updates
	Hospital Providers
6	General Updates
7	Hospital Transformation Program (HTP) Program Updates
8	Medicare Crossover Claim Billing and Payment Updates for State
0	Funded Mental Health Institutes (MHIs)
	Hospital, Lab and Physician Services
8	Urinalysis Test Policy Clarification
-	
	Pharmacies and All Medication-Prescribing Providers
9	Drug Utilization Review Update to Pharmacy Prior Authorization
5	Form for Medications Administered in a Member's Home or in a
	LTCF by a Healthcare Professional
9	Preferred Drug List (PDL) Announcement of Preferred Products
	Pharmacy Providers
13	Total Annual Prescription Volume (TAPV) Survey
	Dharmaou Drowidere Dhusisian Corriges
	Pharmacy Providers, Physician Services
14	Tobacco Cessation Reminder
	Physician-Administered Drug (PAD) Providers
14	PAD Billing Guidance
17	Quarter 4 Rate Updates 2019
	Physician Services
17	Abortion Services Update
	Provider Billing Training Sessions
18	October and November 2019 Provider Billing Training Sessions

Did You Know?

The best way for providers to refund Health First Colorado (Colorado's Medicaid Program) payments is to submit an electronic adjustment. The amount due will be subtracted from the future payments for processed claims and will appear on a Remittance Advice (RA). If providers choose to submit a paper check, it must be accompanied by a <u>Refund to Health First Colorado or Return</u> <u>Warrant Form</u>, located on the <u>Provider Forms web</u> <u>page</u> under the Claim Forms and Attachments drop-down, for the full amount of the check. The member ID and Internal Control Number (ICN) must be included.

All Providers

Enrollment Application Date of Birth (DOB) Requirement Reminder

Providers are reminded to enter the actual DOB for individuals, owners and managing employees, in the appropriate sections (Provider Identification and Disclosures) of the enrollment application. In accordance with federal screening rule 42 CFR § 455.104 and Colorado Code of Regulations 10 CCR 2505-10 8.125.15, a verification is completed for all individuals, and when the DOB does not match, the application is returned for correction(s) or denied.

Improving health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.

Updated Process for Member Date of Death (DOD) Verification

A future update to the Colorado interChange will match the member DOD to the DOD in the Colorado Benefits Management System (CBMS), the eligibility system of record. This update will ensure Colorado interChange has valid and complete member information and prevent billing issues for providers.

<u>Clinics, Non-Physician Practitioner, Occupational</u> <u>Therapist, Rehabilitation Agencies</u>

Non-Covered Modalities Under the Occupational Therapy Benefit

The following modalities are not covered under the occupational therapy benefit for Health First Colorado due to not meeting the medical necessity standard. See <u>10 C.C.R. 2505-10, § 8.076.1.8</u>.

- Eye Movement Desensitization and Reprocessing
- Internal Family Systems
- Relationship Development Intervention

Refer to the <u>Outpatient Physical and Occupational Therapy billing manual</u> for more information, located on the <u>Billing Manuals web page</u> under the CMS 1500 drop-down section.

Contact Alex Weichselbaum at <u>Alex.Weichselbaum@hcpf.state.co.us</u> with any questions.

<u>Dental Providers</u>

Child Health Plan *Plus* (CHP+) Prenatal Dental Benefit

Effective October 1, 2019, dental services will be available for CHP+ prenatal women. The benefits are the same as services provided for current CHP+ children except for orthodontics (braces). These benefits include:

- Diagnostic services (exams and x-rays)
- Preventive (fluoride, sealants and cleanings)
- Basic restorative services (fillings)
- Endodontic (root canals)
- Emergency dental services

The annual maximum allowable is \$1,000 per calendar year (July 1 through June 30) while the member is eligible and enrolled. As with all CHP+ benefits, families with a higher income may be required to pay a small fee (co-pay) when they receive services.



Contact DentaQuest at 1-855-225-1731, TTY 711, for more information on this policy or billing.

Home & Community-Based Service (HCBS) Providers

Unit Limit Update for Procedure Code T2003

Effective August 1, 2019, procedure code T2003 (non-medical transportation) on the Supported Living Services (SLS) waiver had the unit limitation updated to twenty (20) units per month. Unit limits were set at two round trips per week; when exceeded, providers received a denial for Explanation of Benefits (EOB) 2383 - "Non-Medical Transportation HCBS-SLS waiver benefit limited to sixteen (16) units per month." In months in which there are five weeks, claims were being denied.

Claims denied for this were mass adjusted back to July 1, 2017. The overall limit of 208 units will remain unchanged.

Contact Tammie Taylor at Tammie.Taylor@state.co.us with any questions.

Home & Community-Based Service (HCBS), Home Health, Hospice, Private Duty Nursing, Outpatient Therapy, and Durable Medical Equipment Providers

Electronic Visit Verification (EVV) Training Announcement

The <u>21st Century CURES Act</u>, passed in December 2016, requires state Medicaid programs to implement EVV for Personal Care and Home Health services. Per section 12006, all states must implement an EVV system to avoid a reduction in federal Medicaid funding. EVV is an electronic-based system that verifies when provider visits occur and documents the precise time services begin and end, ensuring that members receive authorized services. For federal compliance, all EVV systems must collect the six points of data listed below.

- 1. Type of service performed
- 2. Individual receiving the service
- 3. Date of the service
- 4. Location of service delivery
- 5. Individual providing the service
- 6. Time the service begins and ends

Within calendar year 2020, the Department of Health Care Policy & Financing (the Department) will **require** Health First Colorado providers of EVV mandated home and community-based and state plan services to use EVV. Colorado is implementing EVV for federally required services and additional services that are similar in nature and service delivery. A list of services that require EVV in Colorado is below.

Participation in Colorado's EVV implementation is **mandatory** for all agencies that provide the following programs and services. Provider agencies not in compliance with EVV upon Department mandate may experience a disruption in reimbursement.

	Services Mandated for Colorado EVV Implementation*				
•	Behavioral Therapies (provided in the home or community)	•	Life Skills Training		

Services Mandated for Colo	prado EVV Implementation*
 Consumer Directed Attendant Support Services (CDASS) Durable Medical Equipment (requiring inhome setup) - delayed Home Health: RN, LPN, CNA, PT, OT, SLP Homemaker Hospice Independent Living Skills Training (ILST) In-Home Support Services (IHSS) 	 Occupational Therapy (provided in the home) Physical Therapy (provided in the home) Pediatric Behavioral Health Pediatric Personal Care Personal Care Private Duty Nursing Respite (provided in the home or community)
	Speech Therapy (provided in the home)Youth Day

*Services subject to change

*Facility-based Per Diem Services, Managed Care, Program of All-inclusive Care for the Elderly (PACE) and other Capitated Services

Colorado Implementation

The Colorado EVV program will deploy a **hybrid model**. A hybrid model means that a provider agency may choose to use the State EVV Solution at no cost or utilize an alternate EVV vendor. The Department has subcontracted with Sandata Technologies for State EVV Solution. The State Solution will utilize three EVV technologies: mobile application, telephony and a provider web portal. Providers who choose to utilize an alternate EVV solution must ensure that their system is configured to Colorado EVV rules and requirements.

A list of <u>vendors who have interfaced with Sandata in other states</u> is available on the <u>Electronic Visit</u> <u>Verification web page</u> under the Resources button. Interface time may be reduced by choosing a vendor from this list. The Department does not endorse any vendor or recommend using a vendor from this list. It is each provider's responsibility to have a functional EVV solution by the date mandated by the Department. The Department anticipates mandating EVV in late summer 2020.

Option One: State EVV Solution

Training Overview

- Training is free and mandatory
- Training registration is open
- Credentials for the State EVV Solution will be sent after September 30, 2019
- Classroom and webinar trainings are for providers using the State EVV Solution
- Limited to two staff members per provider ID for classroom and webinar modalities
- Self-paced training is for providers using the State EVV Solution and providers using an alternate EVV system

Register for State Solution Provider Training

Training Resources

- Provider Training Registration Quick Reference Guide
- EVV Agency Provider Participant Training Guide
- EVV Training Supplemental Materials Guide
- <u>Electronic Visit Verification State Solution Provider Information</u>

Option Two: Provider Choice System

Providers who will be using a third-party EVV vendor will utilize two instructional documents for interfacing with the Sandata Data Aggregator:

- Requirement Specification for Receipt of Alternate Electronic Visit Verification Systems Data (altEVV)
 - This document contains generic specifications which outline the requirements for using the Sandata Real Time Interface. This interface includes clients, employees, visits, and their associated calls as well as the ability to send data related to visit modifications.
- Colorado HCPF Third Party EVV Companion Guide to Third Party Alternate EVV System Specification
 - This document is an addendum which outlines the requirements specific to the Colorado's EVV program. This document explains all required fields, data, and expected values required by Colorado EVV.

Training Overview

- Training is free and mandatory
- Training registration is open
- Aggregator training that is available may be completed before or after interface testing
- Aggregator log-in credentials will be sent after September 30, 2019
- Self-paced eLearning is the only training option available to Provider Choice System users

Register for Provider Choice System Training

Questions About Training?

Contact the EVV Provider Help Desk at 855-871-8780 or <u>CO-HCPF-</u> <u>EVVProviderHelpdesk@etraconline.net</u> with any questions about training.

Learn More

Information and updates about EVV are available on the <u>Electronic Visit</u> <u>Verification web page</u>. Providers are encouraged to visit this web page often for the latest EVV news and any upcoming training announcements.

The Department looks forward to working with providers on successful EVV implementation. Contact <u>evv@state.co.us</u> with any questions on EVV.

Hospice Providers

Hospice Facility Fiscal Year 2019-2020 Rate Updates

The Department has finalized the Hospice Facility rates effective October 1, 2019, through September 30, 2020. All facility rates have been loaded in the Colorado interChange and reimbursement should reflect updated rates for all claims billed for dates of service on or after October 1, 2019.

A Hospice Room and Board fee schedule effective October 1, 2019, through September 30, 2020, will be provided with the Department communication upon implementation of the rates.

Contact Victoria Martinez at <u>Victoria.L.Martinez@ state.co.us</u> for additional support or with questions regarding rates. Contact Alex Koloskus at <u>Alexandra.Koloskus@state.co.us</u> for additional support or with questions regarding policy.

Hospital Providers

General Updates

Inpatient Hospitals

CMS Approval for Fiscal Year (FY) 2019-20 Inpatient Hospital Base Rates

The Department has received notification from the Centers for Medicare & Medicaid Services (CMS) that FY 2019-20 Inpatient Hospital Rates were approved.

- New base rates were loaded into system as of September 5, 2019.
- As of September 16, 2019, all inpatient hospital claims with a last date of service between July 1, 2019, and September 4, 2019, will be reprocessed.

October 2019 ICD-10 Update

The Department will be updating the 3M software to accommodate the updated ICD-10 code set. Colorado will continue using APR-DRG Version 33 with this update.

Contact Diana Lambe at Diana.Lambe@state.co.us with any questions.

Inpatient Hospital Per Diem Rate Group

Visit the <u>Inpatient Hospital Per Diem Reimbursement Group web page</u> for information on meetings, posted rates and announcements on Long Term Acute Care and Rehabilitation Per Diem Rates.

There are no meetings currently scheduled. Past meeting materials are available on the <u>Hospital</u> <u>Stakeholder Engagement Meetings web page</u>.

Outpatient Hospitals

October 2019 Enhanced Ambulatory Patient Grouping (EAPG) Module Update

The Department will be updating the 3M software which utilizes the EAPG methodology to version 2019.3.0 during the first week of October. This change will accommodate the quarterly Healthcare Common Procedure Coding System (HCPCS)/Current Procedural Terminology (CPT) updates as well as the updated ICD-10 code set. Colorado will continue using EAPG version 3.10 with this update.


Contact Andrew Abalos at Andrew.Abalos@state.co.us with any questions regarding EAPG.

All Hospital Providers

Bi-Monthly Hospital Stakeholder Engagement Meetings

The Department will continue to host bi-monthly Hospital Engagement meetings to discuss current issues regarding payment reform and operational processing. The next meeting is scheduled for Friday, November 1, 2019, 9:00 a.m.-12:30 p.m. at 303 E 17th Ave, Denver, Conference Room 7B & 7C. Calendar Year 2019 is currently posted and Calendar 2020 schedule will be announced at our next meeting.

Sign up to receive the Hospital Stakeholder Engagement Meeting newsletters.



<u>Visit the Hospital Engagement Meeting web page for more details, meeting schedule and past meeting materials.</u>

Contact Elizabeth Quaife at <u>Elizabeth.Quaife@state.co.us</u> with any questions or topics to be discussed at future meetings. Advance notice will provide the Rates team time to bring additional Department personnel to the meetings to address different concerns.

Hospital Transformation Program (HTP) Program Updates

Update on HTP Communications Archives

The <u>HTP Newsletters and Communications Archive web page</u> was restructured to give more transparency to historic communications between the Department and stakeholders. In addition to archives of past editions of the HTP Newsletters, the web page now includes, and will continue to include, additional communications regarding HTP. Visit the <u>HTP Newsletter and Communications Archive web page</u> for more information.

Scoring Framework Posted

<u>The Scoring Framework</u>, the revised version of how measures will be scored, has been posted to the <u>Colorado Hospital Transformation Program web page</u> under Hospital Transportation Program Overview & Framework. Hospitals will be evaluated on both state and local measures, with local measures being chosen by hospitals to specifically reflect the needs in their community as identified through the Community and Health Neighborhood Engagement (CHNE) process. The document outlines the program pieces that have associated penalties and incentives, and at what levels.



<u>The proposal</u> for calculating the total required effort for measures is that each hospital will be required to work on a set of statewide and local measures equal to 100 points. The number, mix and points per measure will vary according to hospital size, defined by bed count or specialty type. As it has been throughout the development of the HTP, the development process has been open, transparent and inclusive of stakeholder and community input and feedback.

The work of the Colorado Hospital Association (CHA) and the various workgroups who participated in this important collaboration is greatly appreciated. Contact the HTP team at <u>COHTP@state.co.us</u> with any questions or comments.

Rural Support Fund

The Department is beginning the process of holding preliminary meetings with a small group of hospitals to discuss the Rural Support Fund component of the HTP. Pending approval from the Centers for Medicare & Medicaid Services (CMS), this part of the program will be under 1115 waiver authority to provide additional resources for non-resort, critical access and frontier hospitals. Additional information about this component of the program will be forthcoming and can be found in future editions of the HTP Newsletter.

Providers are encouraged to visit the Colorado <u>Hospital Transformation Program web page</u> as well as read past editions of the HTP Newsletter on the <u>HTP Newsletter and Communications Archive web page</u>.

Contact Courtney Ronner at <u>Courtney.Ronner@state.co.us</u>, Hospital Relations and Communication Manager, at 303-866-2699 with any additional questions about the HTP.

Medicare Crossover Claim Billing and Payment Updates for State Funded Mental Health Institutes (MHIs)

Effective October 2, 2019, the Colorado interChange will be updated to ensure that State Funded MHIs are paid correctly for Medicare crossover claims. Services that have been provided since March 1, 2017, with incorrect payment will be reimbursed.

State Funded MHIs will be able to bill Medicaid for room and board and Medicare for the ancillary expenses. MHIs must manually enter the Medicare ancillary payment and the final payment should equal the Medicaid allowed amount payment (per diem x days) - Medicare payment (ancillary x days). The Provider Web Portal will be updated to allow providers to use a new Part B only/Part A checkbox when billing inpatient crossover claims for members that have TXIX benefits and Medicare Part A benefits during the stay.


Hospital, Lab and Physician Services

Urinalysis Test Policy Clarification

This policy notice is intended to clarify the Department's requirements for substance-specific confirmatory tests ("confirmatory tests") as described in the <u>September 2017 Provider Bulletin (B1700403)</u>.

Beginning October 1, 2017, the Department implemented unit limits on presumptive drug tests [Current Procedural Terminology (CPT) codes 80305, 80306 and 80307]. The unit limit is four (4) presumptive drug tests per month per client for each code. This unit limit applies to all provider types.

The Department also implemented a billing policy for confirmatory tests performed outside the hospital setting. Health First Colorado will reimburse providers for confirmatory tests only if they meet the medical necessity standard. See <u>10 C.C.R. 2505-10, § 8.076.1.8</u>. If a provider of laboratory services is unable to demonstrate that a confirmatory test meets the definition of medical necessity, the test will not be eligible for reimbursement.



When processing claims, the Department will consider a positive or inconclusive presumptive test to be evidence of medical necessity for confirmatory tests. The presumptive test must have been administered within two (2) days prior to the confirmatory test. The positive or inconclusive results of the presumptive test must be scanned and attached to the claim for the confirmatory test.

If no presumptive test is performed prior to a confirmatory test, the provider will be required to include supporting documentation that demonstrates the medical necessity of the confirmatory test when submitting the claim.

Confirmatory tests without the corresponding positive or inconclusive presumptive test attached to the claim may not be eligible for reimbursement.


Contact Raine Henry at <u>Raine.Henry@state.co.us</u> with any questions concerning this policy.

Pharmacies and All Medication-Prescribing Providers

Drug Utilization Review Update to Pharmacy Prior Authorization Form for Medications Administered in a Member's Home or in a Long Term Care Facility (LTCF) by a Healthcare Professional

The Department currently allows for drugs administered by a healthcare professional to be payable through the pharmacy benefit when administered in the member's home or when administered in a LTCF. Drugs administered by a healthcare professional in a provider's office or clinic are billed through the medical benefit.

As part of changes made on August 1, 2019, additional information is required when submitting prior authorization (PA) requests (processed by Magellan) for medications administered by a healthcare professional when billed through the pharmacy benefit. The <u>Pharmacy Prior Authorization Form</u> was recently updated to better clarify what information is needed from providers when submitting these types of requests. The <u>Pharmacy Prior Authorization Form</u> can be accessed on the <u>Pharmacy Resources web page</u> under the Other Forms section.



PA requests for drugs that are administered by a healthcare professional will require the following additional information to be included:

- For medications administered in a member's home by a home health agency or healthcare professional (home health administered): Name of home health agency or healthcare professional; phone number; and when applicable for home health agencies, date and authorization number for current home health authorization on file.
- For members receiving medication in an LTCF: Name of facility and phone number.

For drugs that are not administered by a healthcare professional in the home or LTCF, there is no additional information needed and this section of the form does not need to be filled in. As a reminder to pharmacies, a '12' may be entered in the Place of Service field (307-C7), but only on claims for medication administered by a healthcare professional in the member's home.

Contact the Magellan Rx Management Pharmacy Call Center at 1-800-424-5725 for pharmacy claims or PA processing questions.

Contact Brittany Schock at Brittany.Schock@state.co.us with any other questions.

Preferred Drug List (PDL) Announcement of Preferred Products

The following drug classes and preferred agents will become effective October 1, 2019, for Health First Colorado:

Anticoagulants					
Enoxaparin syringe	Lovenox vial	Pradaxa	Warfarin	Xarelto 10mg, 15	Xarelto Dosepack
	(BNR			mg, 20mg tablet	
Anticonvulsants					
Carbamazepine (all	generic	Clobazam	Clonazepam	Divalproex	Dilantin 30mg
formulations with exception of		tablet			capsule

Ethosuxamide Felbatol Lamotrigine tablet (bulk packaging)/chewable Oxcarbazepine Levetiracetam Levetiracetam ER Phenobarbital Phenytek Phenytoin Primidone Tegretol suspension Topiramate tablet/sprinkle Valproic Acid Zonisamide Image: Suspension Suspension Alendronate 5mg, 10mg, 35mg, 70mg tablet Ibandronate tablet Ibandronate tablet Suspension Neupogen vial/syringe Biguanides Metformin ER 500mg tablet (generic Glucophage XR) Meege No changes DPP4 Inhibitors Suspension Janumet Janumet XR Januvia Tradjenta Imoviana Jardiance Thizolidinediones SGLT2 Inhibitors Imoviana Jardiance Bydureon pen/kit Byetta Victoza Imoviana Jardiance Farxiga Invokana Jardiance Imoviana Imoviana Byogitazone Col Motility Agents Movantik Imoviana Berinert Gi Motility Agents Movantik Imoviana Berinert Oxybutynin R Guyoutynin R <td< th=""><th colspan="7">suspension; brand Tegretol suspension preferred)</th></td<>	suspension; brand Tegretol suspension preferred)						
packaging)/chewabie respective Levetiracetam ER Phenobarbital Phenytek Phenytoin Primidone Tegretol Topiramate tablet/sprinkle Valproic Acid Zonisamide Suspension Atendronate Smg, 10mg, 35mg, 70mg tablet Ibandronate tablet Ibandronate tablet Neupogen vial/syringe Biguanides Suspension Neutormin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Support No changes SUT2 Inhibitors Janumet Janumet XR Januvia Tradjenta SUT2 Inhibitors Support Nitical Support SUT2 Inhibitors Farsiga Invokana Jardiance Pioglitazone Thiazolidinediones Support Amitiza Linzess Movantik							
Image: Stand	Linosuxamide	reibatot	packaging)/chewable			Levellacetain	
Topiramate tablet/sprinkle Valgroic Acid Zonisamide Agents Bone Resorption Suppression and Related Agents Alendronate 5mg, 10mg, 35mg, 70mg tablet Ibandronate tablet Colony Stimulating Factors Neupogen vial/syringe Biguanides Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg tablet SIT State	Levetiracetam ER	Phenobarbital	Phenytek	Phenytoin	Primidone	-	
Bone Resorption Suppression and Related Agents Alendronate 5mg, 10mg, 35mg, 70mg tablet Ibandronate tablet Colony Stimulating Factors Neupogen vial/syringe Biguanides Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Meglittinides No changes No changes DPP4 Inhibitors Janumet Janumet XR Januvia Tradjenta	Topiramato tablet/	prinklo	Valarais Asid	Zonicamido		suspension	
Alendronate Smg, 10mg, 35mg, 70mg tablet bandronate tablet Colony Stimulating Factors Neupogen vial/syringe Biguanides Metformin ER 500mg tablet (generic Glucophage XR) Janumet Janumet XR Janumet Statts IN GLPI Agonists Stimulating Agents Farxiga Invokana Jardiance Thiazolidinediones Pioglitazone Amylin Analogs No changes Retacrit GL Motility Agents Amitiza Invereditary Angioedema <t< td=""><td>Topiramate tablet/s</td><td></td><td></td><td></td><td>d Agonts</td><td></td></t<>	Topiramate tablet/s				d Agonts		
Colony Stimulating Factors Neupogen vial/syringe Biguanides Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Meglitinides Metformin ER 500mg tablet (generic Glucophage XR) Meglitinides Metformin ER 500mg tablet (generic Glucophage XR) Meglitinides DPP4 Inhibitors Janumet Janumet XR GLPI Agonists Bydureon pen/kit Bydureon pen/kit Bydureon pen/kit Stimulating Agents Farxiga Invokana Jardiance Thiazolidinediones Figlitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit Gl Motility Agents Amylin Analogs No changes Bydureon benchicker Bag Metholity Agents Amylin Analogs No changes Bydureon benchicker Bag Bydureon benchick	Alondronato 5mg 1						
Neupogen vial/syringe Biguanides Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin 500mg, 850mg, 1000mg tablet No changes DPP4 Inhibitors Janumet XR Janumet XR Januvia Tradjenta GLPI Agonits Bydureon pen/kit Byetta Victoza Jardiance Thiazolidinediones Pioglitazone Thiazolidinediones Pioglitazone Thiazolidinediones Pioglitazone Carty Inhibitors Retacrit GI Motility Agents Armitiza Linzess Mo changes Mo changes Mo changes Mo changes Mo changes No changes Simulating Agents Retacrit GI Motility Agents Armitiza Linzess Movantik Hereditary Angioedema Berinert Firazyr Haegarda Ophhalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin IR Cybutynin IR Cybutynin IR Cybutynin IR Cybutynin IR Cybutynin IR Cybutynin IR Salts IR Amphetamine Salts IR CitraNatal IC CitraNatal IC CitraNatal IC CitraNatal CitraNatal Concept DHA Concept OB Prenatal Vitamins Prenatal Vitami	Alendronale Jing, I	onig, Joing, Joing (
Biguanides Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Metformin ER 500mg tablet (generic Glucophage XR) Metformin ER 500mg tablet (generic Glucophage XR) No changes DPP4 Inhibitors Janumet X Janumet X Janumet X Janumet Victoza Victoza GLPI Agonists Bydureon pen/kit Byetta Victoza Thiazolidinediones Farxiga Invokana Jardiance Thiazolidinediones Pioglitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Movantik Berinert GI Motility Agents Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin IR tablet Motilate	Neupogen vial/svrin	0e	Colony Stimu	ating ractors			
Metformin 500mg, 850mg, 1000mg tablet Metformin ER 500mg tablet (generic Glucophage XR) Janumet XR Januvia Tradjenta GLP1 Agonists Super Sup			Bigua	nides			
Meglitinides No changes No changes DPP4 Inhibitors Janumet Janumet XR Januvia Tradjenta Bydureon pen/kit Byetta Victoza	Metformin 500mg, 8	50mg, 1000mg tab			00mg tablet (generi	ic Glucophage XR)	
No changesDPP4 InhibitorsJanumet XRJanuyaTradjentaGLPI AgonistsBydureon pen/kitByettaVictozaBydureon pen/kitByettaVictozaSGLT2 InhibitorsFarxigaInvokanaJardianceThiazolidinedionesPioglitazoneColspan="2">Amylin AnalogsNo changesNo changesRetacritGli Motility AgentsAmitizaInizesMovantikBerinertLinzessFirazyrHereditary AngioedemaSolytautinic ImmunomodulatorsStimulating AgentsColspan="2">ToviazStimulatis and Related AgentsGelniqueOxybutynin syrupOyeractive Bladder AgentsStimulants and Related AgentsStimulants and Related AgentsArmodafinitAtomoxetineAmpletamine Salts IRAmphetamine Salts ERDexmethylphenidate IR (BNR)Guanfacine ER (BNR)ModafinitCitraNatal SERPrenata VitamineConcerta Natal 	metrorinin soonig, e						
DPP4 Inhibitors Janumet Janumet XR Januvia Tradjenta Image: Second Sec							
Janumet XR Januvia Tradjenta GLPI Agonists Bydureon pen/kit Byetta Victoza SGLT2 Inhibitors Farxiga Invokana Jardiance Thiazolidinediones Pioglitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Movantik Hereditary Angioedema Berinert Firazyr Haegarda Berinert Firazyr Haegarda Berinert Firazyr Haegarda Glandility Agents Restasis single-use vial Ophthalmic Immunomodulators Restasis single-use vial Gelnique Oxybutynin R Gelnique Oxybutynin R Syrup Stimulatis and Related Agents Amodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts IR Methylphenidate IR Dexmethylphenidate IR CitraNatal 90 DHA CitraNatal 90 DHA CitraNatal Concept DHA Concept OB M-Natal Plus Prenatal Vitamin Plus Low Iron Prenatal Vita Mona Prenatal Plus Prenatal Vita Mona Prenatal Vita Mona Prenatal Vita Mona Prenatal Vita Mona Prenatal Vita Mona Prenatal Vitamin Plus Low Iron Prenatal Vita Mona Prenatal							
GLPI Agonists Bydureon pen/kit Byetta Victoza SGLT2 Inhibitors SGLT2 Inhibitors Farxiga Invokana Jardiance Pioglitazone Amylin Analogs No changes Movantik Retacrit GI Motility Agents Movantik Berinert Firazyr Haegarda Ophthalmic Immunomodulators Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin IR tablet Amphetamine Salts ER Methylphenidate IR Perenatal Vitamins Guanfacine ER (BNR) Guanfacine ER Methylphenidate ER (generic Calin XR (BNR) Guanfacine ER Methylphenidate ER (generic Calin XR Calm CitraNatal Assure CitraNatal 90 DHA CitraNatal Assure CitraNatal Calm CitraNatal DHA CitraNatal Harmony Complete Natal DHA Concept DHA Concept OB M-Natal Plus PNV OB+DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Vitamin Plus Low Iron Plus PrePLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus	Janumet	Janumet XR	1				
Bydureon pen/kit Byetta Victoza SGLT2 Inhibitors Farxiga Jardiance Farxiga Jardiance Thiazolidinediones Pioglitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Movantik Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin Et tablet Toviaz Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR (BNR) Modafinil Vyvanse capsule/chewable Orenatal Vitamins CitraNatal B ^o CitraNatal B ^o OHA Concept DHA Concept OB M-Natal Plus <td< td=""><td>Vananiee</td><td>Valiance / at</td><td></td><td></td><td></td><td></td></td<>	Vananiee	Valiance / at					
SGLT2 Inhibitors Farxiga Invokana Jardiance Finazolidinediones Thiazolidinediones Pioglitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Marce Hereditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin ER tablet Toviaz Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR (generic (BNR) Methylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Vyvanse capsule/chewable Oridata Ig 0 DHA CitraNatal Assure CitraNatal B- Calm CitraNatal CitraNatal Ig Otha CitraNatal RX Harmony CitraNatal RX Harmony Complete Natal Concept DHA Concept OB M-Natal Plus Nestabs PNV OB+DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus Prenatal Vitamin Plus Low Iron Plus	Bydureon pen/kit						
Farxiga Invokana Jardiance Thiazolidinediones Pioglitazone Amylin Analogs No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Movantik Hereditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Overactive Bladder Agents Stimulants and Related Agents Modafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR (generic Rialin IR) Modafinil Verenatal Vitamins CitraNatal & Harmony Dexemethylphenidate IR (generic Rialin IR)<							
Thiazolidinediones Pioglitazone Amylin Analogs No changes No changes Retacrit GI Motility Agents Movantik Movantik Movantik Movantik Hareditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin Syrup Coveractive Bladder Agents Gelnique Oxybutynin Syrup Toviaz Stimulants and Related Agents Armodafinil Atomozetine Amphetamine Salts IR Amphetamine Salts ER Methylphenidate IR (generic (BR) Orentat Vitamins CitraNatal Po (StraNatal 90 DHA CitraNatal B- CitraNatal B- Calm CitraNatal Harmony CitraNatal RX Harmony Concept DHA Con	Farxiga		-		Jardiance		
Amylin Analogs No changes No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Movantik Metacrite Berinert Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR				inediones			
Amylin Analogs No changes No changes Erythropoiesis Stimulating Agents Retacrit GI Motility Agents Amitiza Linzess Movantik Metacrite Berinert Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR Amphetamine Salts IR	Pioglitazone						
No changesErythropoiesis Stimulating AgentsRetacritGI Motility AgentsAmitizaMovantikHereditary AngioedemaBerinertFirazyrHaegardaOphthalmic ImmunomodulatorsRestasis single-use vialOveractive Bladder AgentsGelniqueOxybutynin syrupOxybutynin IR tabletOxybutynin ER tabletToviazArmodafinilAtomoxetineAmphetamine Salts IR (BNR)Amphetamine Salts ERDexmethylphenidate IR (generic Ritalin IR)ModafinilVeractal VitaminesCitraNatal 90 DHACitraNatal CalmCitraNatal DHACitraNatal Concept DHAConcept OB M-Natal PlusNestasisPrenatal Vitamin Pus Low IronPrepLUSTotiazTotiazStimulatis and Related AgentsConcertaModafinilAtomoxetineAtomoxetineAmphetamine Salts IR (BNR)Amphetamine Salts IR (BNR)Amphetamine Salts ERConcertaModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHA<			Amylin /	Analogs			
Erythropoiesis Stimulating Agents Gl Motility Agents Movantik Movantik Movantik Movantik Movantik Movantik Movantik Movantik Hareditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Overactive Bladder Agents Stimulants and Related Agents Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR Generic Ritalin IR Guanfacine ER Methylphenidate ER (generic Concerta) Methylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal 90 DHA CitraNatal Calm CitraNatal Harmony CitraNatal RX Assure Calm DHA Harmony PNV OB+DHA							
Gl Motility Agents Amitiza Linzess Movantik Hereditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Overactive Bladder Agents Torviaz Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal GitraNatal B- CitraNatal 90 DHA CitraNatal Assure Calm DHA CitraNatal RX <					5		
Amitiza Linzess Movantik Hereditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin ER tablet Toviaz Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR Focalin XR (BNR) Guanfacine ER Methylphenidate ER (generic Concerta) Methylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal CitraNatal Assure CitraNatal B- Calm CitraNatal DHA CitraNatal Harmony CitraNatal RX PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus Prenatal Vitamin Plus Low Iron PrepLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus	Retacrit						
Hereditary Angioedema Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin ER tablet Toviaz Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR Focalin XR (BNR) Guanfacine ER Methylphenidate ER (generic Concerta) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal 90 DHA CitraNatal Assure CitraNatal B- Calm CitraNatal DHA CitraNatal Harmony CitraNatal RX Harmony Complete Natal DHA Concept DHA Concept OB M-Natal Plus Nestabs PNV OB+DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus Prenatal Vitamin Plus Low Iron Plus Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus			GI Motilit	y Agents			
Berinert Firazyr Haegarda Ophthalmic Immunomodulators Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin It tablet Oxybutynin IR Oxybutynin ER tablet Toviaz Stimulants and Related Agents Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR Focalin XR (BNR) Guanfacine ER Methylphenidate ER (generic (BNR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal CitraNatal Assure CitraNatal B- Calm CitraNatal DHA CitraNatal Harmony CitraNatal RX (CitraNatal RX PNV OB+DHA Omplete Natal DHA Concept DHA Concept OB M-Natal Plus Nestabs PNV OB+DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus Prenatal Plus Prenatal Vitamin Plus Low Iron PrepLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus	Amitiza		Linzess		Movantik		
Ophthalmic ImmunomodulatorsRestasis single-use vialOveractive Bladder AgentsGelniqueOxybutynin syrupOxybutynin IR tabletOxybutynin ER tabletToviazGelniqueOxybutynin syrupOxybutynin IR tabletOxybutynin ER tabletToviazStimulants and Related AgentsArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ER Oucreta)Methylphenidate ER (generic Concerta)OutraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RX HarmonyConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal PlusPrenatal Vitamin Plus Low Iron PlusPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
Restasis single-use vial Overactive Bladder Agents Gelnique Oxybutynin syrup Oxybutynin IR tablet Oxybutynin ER tablet Toviaz Armodafinil Atomoxetine Amphetamine Salts IR Amphetamine Salts ER Dexmethylphenidate IR Focalin XR (BNR) Guanfacine ER Guanfacine ER Methylphenidate ER (generic Concerta) Methylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal 90 DHA CitraNatal Assure CitraNatal B- Calm CitraNatal DHA CitraNatal Harmony CitraNatal RX Harmony PNV OB+DHA Concept DHA Concept OB M-Natal Plus Nestabs PNV OB+DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus Prenatal Vitamin Plus Low Iron PrePLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus							
Overactive Bladder AgentsGelniqueOxybutynin syrupOxybutynin IR tabletOxybutynin ER tabletToviazArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ER Concerta)Methylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHA CitraNatal AssureCitraNatal CalmCitraNatal DHACitraNatal HarmonyCitraNatal PNV OB+DHAOmplete Natal DHAConcept DHA PNV OB+DHAConcept OB Prenaissance PlusM-Natal Plus Prenatal PlusNestabs Pnenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
GelniqueOxybutynin syrupOxybutynin IR tabletOxybutynin ER tabletToviazStimulants and Related AgentsArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ER Guanfacine ERMethylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RX HarmonyComplete Natal DHAConcept DHAConcept OBM-Natal Plus Prenatal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FA PlusPrenaissance PlusPrenatal Plus Prenatal Vit AdvancePrenatal Vite GTVol-Plus	Restasis single-use v	/ial					
syruptabletStimulants and Related AgentsArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ERMethylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RX HarmonyComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus			Overactive Bl				
Stimulants and Related AgentsArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ERMethylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RXComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus	Gelnique			Oxybutynin ER	tablet	Toviaz	
ArmodafinilAtomoxetineAmphetamine Salts IRAmphetamine Salts ERDexmethylphenidate IRFocalin XR (BNR)Guanfacine ERMethylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RXComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus		syrup		Polatod Agonts			
Dexmethylphenidate IRFocalin XR (BNR)Guanfacine ERMethylphenidate ER (generic Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsPrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RXComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
(BNR)Concerta)Methylphenidate IR (generic Ritalin IR)ModafinilVyvanse capsule/chewablePrenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RX HarmonyComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
Methylphenidate IR (generic Ritalin IR) Modafinil Vyvanse capsule/chewable Prenatal Vitamins CitraNatal 90 DHA CitraNatal RX Complete Natal Concept DHA Concept OB M-Natal Plus Nestabs PNV OB+DHA DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Prenatal Plus Prenatal Vitamin Plus Low Iron PrePLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus							
Prenatal VitaminsCitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal RXComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus	Methylphenidate IR	(generic Ritalin IR)	· · · /	Modafinil			
CitraNatal 90 DHACitraNatal AssureCitraNatal B- CalmCitraNatal DHACitraNatal HarmonyCitraNatal CitraNatal HarmonyComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
AssureCalmDHAHarmonyComplete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus	CitraNatal 90 DHA	CitraNatal			CitraNatal	CitraNatal RX	
Complete Natal DHAConcept DHAConcept OBM-Natal PlusNestabsPNV OB+DHAPNV-Ferrous Fumarate-Docu-FAPrenaissance PlusPrenatal PlusPrenatal Vitamin Plus Low IronPrePLUSTrinatal Rx 1Trust NatalVirt AdvanceVirt-Vite GTVol-Plus							
DHA DHA DHA PNV-Ferrous Fumarate-Docu-FA Prenaissance Plus Prenatal Plus PrePLUS Trinatal Rx 1 Trust Natal	Complete Natal					PNV OB+DHA	
PNV-Ferrous Fumarate-Docu-FA Prenaissance Prenatal Plus Prenatal Vitamin Plus Low Iron PrePLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus	-	concept brint	concept ob	in natur las	1 (cotabo		
PrePLUS Trinatal Rx 1 Trust Natal Virt Advance Virt-Vite GT Vol-Plus		ate-Docu-FA		Prenatal Plus	Prenatal Vitamin F	Plus Low Iron	
	PrePLUS	Trinatal Rx 1		Virt Advance	Virt-Vite GT	Vol-Plus	
Oral Contraceptives		I		aceptives	I		
Monophasic 28							

Altavera 28 0.15- 30	Alyacen 28 1-35	Apri 28 0.15-30	Aubra EQ-28 0.1-20	Aviane 28 0.1-20	Balziva 28 0.4-35
Chateal 28 0.15-30	Cryselle 28 0.3- 30	Cyclafem 28 1- 35	Dasetta 28 1- 35	Drosperinone-Eth E	Estradiol 28 3-30
Elinest 28 0.3-30	Enskyce 28 0.15-30	Estarylla 28 0.25-35	Ethynodiol- Eth Estra 28 1-35	Ethynodiol-Eth Estra 28 1-50	Falmina 28 0.1- 20
Femynor 28 0.25- 35	Isibloom 28 0.15-30	Juleber 28 0.15-30	Kelnor 28 1-35	Kurvelo 28 0.15- 30	Larissia 28 0.1-20
Lessina 28 0.1-20	Levonor-Eth Estra	d 28 0.1-20	Levonor-Eth Est	rad 28 0.15-30	Levora 28 0.15- 30
Lillow 28 0.15-30	Low-Ogestrel 28 0.3-30	Lutera 28 0.1- 20	Marlissa 28 0.15-30	Mili 28 0.25-35	Mono-Linyah 28 0.25-35
Mononessa 28 0.25-35	Norg-Ethin Estra 2	28 0.25-35	Nortrel 28 0.5-35	Nortrel 28 1-35	Ocella 28 3-30
Philith 28 0.4-35	Pirmella 28 1-35	Portia 28 0.15- 30	Previfem 28 0.25-35	Reclipsen 28 0.15-30	Sprintec 28 0.25- 35
Sronyx 28 0.1-20	Syeda 28 3-30	Vienva 28 0.1- 20	Vyfemla 28 0.4-35		
		Monoph	asic 21		
Larin 21 1-20	Larin 21 1.5-30	Norethind-Eth Es Biph	strad 21 1-20	Nortrel 21 1-35	
Azurette 28	Bekyree 28	Desogest-Eth Est		Kariva 28	Lo Loestrin FE 28 1-10
Mircette 28	Viorele 28				
		Triph			
Alyacen 7-7-7 28	Cyclafem 7-7-7 28	Dasetta 7-7-7 28	Enpresse 28	Levonest 28	Levonor-Eth Estrad Triphasic 28
Pirmella 7-7-7 28	Tri-Estarylla 28	Tri-Femynor 28	Tri-Linyah 28	Tri-Lo Estarylla 28	Tri-Lo Marzia 28
Tri-Lo Sprintec 28	Trinessa 28	Tri-Sprintec 28	Tri-Vylibra Lo 28		
		Extende			
Amethia 91 0.03 - 0	.15 - 0.01	Ashlyna 91 0.15-	10-30	Introvale 91 0.15- 30	Jolessa 91 0.15- 30
Levonorgest-Eth Est	rad 0.09-20	Levonorgest-Eth 10-20	Estrad 91 0.1-	Levonorgest-Eth Es	strad 91 0.15-0.03
Levonorgest-Eth Estrad 91 0.15-0.03- 0.01		Levonorgest-Eth 20-25-30 Continuo		Quasense 91 0.15-30	Setlakin 91 0.15- 30
Aurovela FE 1-20	Blisovi FE 1-20	Blisovi FE 1.5- 30	Jasmiel 3-20	Junel FE 1-20	Junel FE 24 1-20
Junel FE 1.5-30	Larin FE 1-20	Larin FE 24 1- 20	Larin FE 1.5- 30	Loryna 3-20	Minastrin FE 24 1-20
Nikki 3-20	Noreth-Eth Estrac	-FE 24 1-20	Noreth-Eth Estr	ad-FE 1-20	Tarina FE 24 1-20
Tarina FE 1-20	Tarina FE 1-20 EQ				
		Norethind	rone Only		
Camila 28 0.35	Deblitane 28 0.35	Errin 28 0.35	Heather 28 0.35	Jencycla 28 0.35	Jolivette 28 0.35
Norethindrone 28 0.	35	Norlyda 28 0.35	Sharobel 28 0.35		

Note: Effective October 1, 2019, Methylphenidate ER tablets (generic Concerta) and Pregabalin capsules (generic Lyrica) will be preferred and brand Concerta tablets and brand Lyrica capsules will be non-preferred. Brand and generic stimulants require age, diagnosis and daily maximum dose limits to be met for approval; brand Concerta tablets and Lyrica capsules will require a Prior Authorization.

Refer to the Preferred Drug List on the Pharmacy Resources web page for details.

Pharmacy and Therapeutics (P&T) Committee Meeting:

Tuesday, October 8, 2019

1:00 p.m. - 5:00 p.m. MT

303 E 17th Ave

Denver, CO 80203

7th Floor Conference Rooms 7A, 7B, 7C



The meeting agenda can be found on the <u>Pharmacy and Therapeutics (P&T)</u> <u>Committee web page</u> under the 2019 Meeting Schedule & Handouts drop-down.

P&T Committee Open Positions:

The P&T Committee has openings for the following positions for January 2020: Pharmacist (2 positions), Other Specialty Physician (3 positions) and Member Representative (1 position).

The actively practicing pharmacist or physician or member representative shall serve two-year terms. Duties, membership and other term details can be found on the <u>Pharmacy and Therapeutics (P&T)</u> <u>Committee web page</u> in the <u>Policies and Procedures Manual</u>, accessible under the Our Members drop-down section.

Interested applicants should send a resume or curriculum vitae (CV) along with a completed <u>Conflict of</u> <u>Interest Form</u> (located on the <u>Pharmacy and Therapeutics (P&T) Committee web page</u> under the Contact Us/Join Us drop-down section) to Brittany Schock at <u>Brittany.Schock@state.co.us</u>, or mail to 1570 Grant Ave, Denver, CO 80203, or fax 303-866-3590. The deadline for this submission is October 25, 2019.

Emergency Supply May Be Requested for Drugs Requiring Prior Authorization (PA)

PA requests submitted by phone and fax are processed within 24 hours of receipt by Magellan. If additional information is required by Magellan for the decision (approval or denial), then the prior authorization request may not be finalized within 24 hours. In this case, the prescriber is asked for the additional information to be provided.

If pharmacist determines that a member needs an emergency supply during the time needed for a PA request to be completed by the provider, the pharmacist may request an override for a 3-day supply, allowable for most medications.

To request a 3-day override for emergency situations while a PA is being processed, contact the Magellan Rx Pharmacy Call Center at 1-800-424-5725, which is available 24 hours a day, 7 days a week. PAs and emergency 3-day supplies can be phoned at 1-800-424-5725 or faxed to 1-888-424-5881 to the Magellan Rx Pharmacy Call Center. Reference <u>Appendix P</u> on the <u>Pharmacy Resources web page</u> for more information.

Pharmacy Providers

Total Annual Prescription Volume (TAPV) Survey

The Department has contracted with Myers and Stauffer to conduct the TAPV survey of pharmacy providers. The prescription volume information submitted by most pharmacy types will be used to determine their dispensing fee for the 2020 calendar year.

Pharmacies which meet the regulatory definition of a Government or Rural Pharmacy will have their dispensing fee determined by their pharmacy type (per 10 CCR 2505-10, Sections 8.800.1 and 8.800.13).

Myers and Stauffer will distribute the surveys to pharmacy providers starting September 30, 2019, and completed surveys must be returned to Myers and Stauffer by October 31, 2019. Pharmacy providers (other than Government or Rural Pharmacies) which do not participate in the prescription volume survey will be placed in the lowest dispensing fee tier (\$9.31).

Completed surveys can be submitted to Myers and Stauffer via email at <u>pharmacy@mslc.com</u>, postal mail at 9265 Counselors Row, Suite 100, Indianapolis, IN 46240, or fax at (317) 566-3203. If not a Government or Rural pharmacy and a survey request was not received, please contact the Myers and Stauffer Pharmacy Help Desk at 800-591-1183 or at the <u>pharmacy@mslc.com</u> to request a survey form.

Total Annual Prescription Volume	Dispensing Fee
0 - 59,999 TAPV	\$13.40
60,000 - 89,999 TAPV	\$11.49
90,000 - 109,999 TAPV	\$10.25
110,000+ TAPV	\$9.31
Rural Pharmacy	\$14.14
Government Pharmacy	\$0.00

Contact the Pharmacy Section at Colorado.SMAC@state.co.us with any questions regarding the survey.

Prescription Drug Acquisition Cost (AAC) Survey

The Department has also contracted with Myers and Stauffer to conduct ongoing acquisition cost surveys for prescription drugs. The Department strongly encourages the participation of all selected pharmacy providers to ensure that AAC reimbursement rates adequately reflect the purchase conditions faced in the market today by Colorado providers. Initial surveys were sent via postal mail on September 30, 2019, to a randomly selected group of pharmacy providers.

Purchase invoices can be submitted to Myers and Stauffer via email at <u>pharmacy@mslc.com</u>; postal mail at 9265 Counselors Row, Suite 100, Indianapolis, IN 46240; or fax at (317)-566-3203. For general inquiries, please contact the Myers and Stauffer Pharmacy Help Desk at 800-591-1183 or at the email listed above. Please note, all submitted invoice data will remain strictly confidential.

Pharmacy Providers, Physician Services

Tobacco Cessation Reminder

Providers are reminded that all first-line smoking cessation medication therapies are eligible for coverage without a prior authorization. This includes:

- Bupropion SR (Zyban®)
- Nicotine patches, gum, lozenges and inhalers
- Varenicline (Chantix®)



Free resources for all smokers and providers are available through the <u>Colorado</u> <u>Quitline</u> or 1-800-QUIT-NOW.

Additional information on coverage for smoking cessation medications can be found in <u>Appendix P</u>, available on the <u>Pharmacy Resources web page</u>.

Information on this topic was previously published in the <u>November 2018 Provider</u> <u>Bulletin (B1800423)</u>.

Physician-Administered Drug (PAD) Providers

PAD Billing Guidance

PADs billed need to include:

- 1. Procedure code (Healthcare Common Procedure Coding System (HCPCS))
 - a. Can include miscellaneous or unlisted J codes and temporary and permanent drug related Q, C, and J codes
- 2. National Drug Code (NDC) of the drug administered
 - a. NDC must be in 11-digit format with no spaces, hyphens or other characters
 - i. If NDC on PAD does not include an 11-digit NDC, provider must add zeros to maintain 5-4-2 formatting
 - 1. XXXX-XXXX-XX = 0XXXX-XXXX-XX
 - 2. XXXXX-XXX-XX = XXXXX-<mark>0</mark>XXX-XX
 - 3. XXXXX-XXXX-X = XXXXX-XXXX-<mark>0</mark>X
- 3. HCPCS units
 - a. For miscellaneous J codes, use HCPCS unit of 1
 - b. For all other PADs, refer to <u>Appendix X-HCPCS/NDC Crosswalk</u> located on the <u>Billing Manuals</u> <u>web page</u> under the Appendices drop-down_ for appropriate HCPCS unit billing
- 4. NDC units
 - a. Calculate the number of units administered according to the NDC labeling
- 5. NDC unit of measure qualifier
 - a. Only the following are acceptable
 - i. GR (gram): ointments, creams, inhalers or bulk powders
 - 1. This unit of measure will primarily be used in the retail pharmacy setting and not for physician-administered drug billing.
 - ii. ML (milliliter): bill if a drug comes in a vial in a liquid form or prefilled syringe
 - iii. EA (each): bill when a drug comes in a vial in powder form and must be reconstituted before administration or with certain, approved tablets, capsules or suppositories

- 6. For all manually priced PADs, an invoice must be attached to the claim
 - Refer to the <u>PAD Fee Schedule located on the Provider Rates & Fee Schedule web page</u> under the Physician Administered Drug Fee Schedule drop-down for additional information on which PADs are manually priced

Note:

- If a PAD claim is billed without an NDC or with an invalid HCPCS/NDC combination, the claim will deny
 - Please refer to <u>Appendix X-HCPCS/NDC Crosswalk</u> located on the <u>Billing Manuals web page</u> under the Appendices drop-down_for valid, reimbursable HCPCS/NDC combinations
- If an invoice is not attached on a manually priced PAD, the claim will deny
 - Please refer to the <u>PAD Fee Schedule</u>, located on the <u>Provider Rates & Fee Schedule web page</u> under the Physician Administered Drug Fee Schedule drop-down, for additional information on which PADs are manually priced
- This policy applies to Professional, Outpatient, EPSDT, and Medicare Crossover claims
- Health First Colorado does not pay for wasted drug from single or multi-use vials; a provider must bill only for the amount of drug administered to the Health First Colorado member
- Calculating NDC Units, HCPCS units, and converting HCPCS units to NDC units
- For miscellaneous PAD codes
 - HCPCS units
 - Bill for a HCPCS unit of 1 when billing J3535, J3490, J3590, J7599, J7699, J7799, J7999, J8498, J8499, J8999 or J9999
 - NDC units
 - Example:

Example.	
Date of service	12/14/2018
Drug and dose	Cinvanti IV 130 MG
administered	
Amount of drug to be	130 MG
billed	
Procedure code (HCPCS)	J3490
HCPCS units	1
NDC (11-digit format)	47426020101
NDC description	Cinvanti 130 MG/18 ML vial
NDC units	18
NDC unit of measure	ML

- For dates of service prior to January 1, 2019, Cinvanti is to be billed with the miscellaneous code J3490
- HCPCS unit is billed as 1 due to the use of the miscellaneous J code for the date of service
- The NDC unit of measure for a liquid, solution or suspension is ML; therefore, the amount billed must be in MLs
- In this example, the quantity administered was the total amount in the vial; therefore, the quantity for NDC units is 18
 - If the dose administered is 100 mg, then the NDC units will be billed as 14 and the NDC unit of measure will remain ML
- For permanent PAD codes
 - Example:

Drug and dose administered	Ciprofloxacin IV 1200 MG
Amount of drug to be billed	1200 MG
Procedure code (HCPCS)	J0744
HCPCS description	Ciprofloxacin for intravenous infusion, 200 MG
HCPCS units	6 (see explanation below)
NDC (11-digit format)	00409476586
NDC description	Ciprofloxacin 200 MG/20 ML vial
NDC units	120 (see explanation below)
NDC unit of measure	ML

- Converting HCPCS units to NDC units
 - Example (from above): Drug and amount administered- Ciprofloxacin IV 1200 mg; HCPCS code- J0744; NDC description- Ciprofloxacin 200 mg/20 mL vl
 - The amount of the drug to be billed is 1200 MG, which is equal to 6 HCPCS units: (1200 MG ÷ 200 MG = 6)
 - The NDC unit of measure for a liquid, solution or suspension is ML; therefore, the amount billed must be converted from MG to ML
 - According to the NDC description for NDC 00409-4765-86, there are 200 MG of ciprofloxacin in 20 ML of solution (200 MG/20 ML)
 - Take the amount to be billed (1200 MG) divided by the number of MG in the NDC description (200 MG): 1200 ÷ 200 = 6
 - Multiply the result (6) by the number of ML in the NDC description (20 ML) to arrive at the correct number of NDC units to be billed on the claim (120): 6 x 20 ML = 120
- Additional Examples

Drug and dose administered	Zaltrap 400 MG
Amount of drug to be billed	400 MG
Procedure code (HCPCS)	J9400
HCPCS description	Injection, ziv-aflibercept, 1 MG
HCPCS units	400
NDC (11-digit format)	00024584101
NDC description	Zaltrap 200 MG/8 ML vial
NDC units	16
NDC unit of measure	ML

Drug and dose administered	Cefepime 500 MG
Amount of drug to be billed	500 MG
Procedure code (HCPCS)	J0692
HCPCS description	Injection, Cefepime hydrochloride, 500 MG
HCPCS units	1
NDC (11-digit format)	60505083404
NDC description	Cefepime HCL 1 GM vial
NDC units	0.5
NDC unit of measure	EA

Drug and dose administered	Cefotetan 6 GM
Amount of drug to be billed	6 GM
Procedure code (HCPCS)	J3490
HCPCS description	Unclassified Drugs
HCPCS units	1
NDC (11-digit format)	63323038620
NDC description	Cefotetan 2 GM vial
NDC units	3
NDC unit of measure	EA

Contact Felecia Gephart at Felecia.Gephart@state.co.us for more information on PAD.

Quarter 4 Rate Updates 2019

The Physician-Administered Drug (PAD) rates for the fourth quarter of 2019 have been updated. The new rates have a start date of October 1, 2019, and are posted to the <u>Provider Rates Fee Schedule web page</u> under the Physician Administered Drug Fee Schedule drop-down section.

Contact Emily Ng at Emily.Ng@state.co.us with any questions about PAD rates.

Physician Services

Abortion Services Update

An abortion is a Health First Colorado covered benefit only under the three listed federal and state mandated conditions:

1) A life-endangering condition for the woman,

and in situations of

- 2) Rape or
- 3) Incest.

Effective October 1, 2019, a medicinally-induced abortion method (utilizing Mifeprex) will be an option for Health First Colorado members who request an abortion associated with a circumstance of rape or incest. This medicinal method is not available for use in situations of maternal life-endangering circumstances. All covered abortion services, including those provided by eligible Mifeprex-prescribing physicians, must be provided in licensed health care facilities.

Billing Requirements for a Medicinally-Induced Abortion:

- 1) Three HCPCS codes (S0190, S0191 and S0199) are identified for use with this abortive method.
 - a. S0190 = MIFEPREX, ORAL, 200 MG (Danco Labs, LLC)
 - i. A valid NDC number must be included with any claim
 - b. S0191=MISOPROSTOL, ORAL, 200 MCG
 - i. A valid NDC number must be included with any claim
 - c. Valid HCPCS NDC combinations can be found in Appendix X, located on the <u>Billing Manuals</u> <u>web page</u> under the Appendices drop-down.

- d. S0199 is used to billed for all associated medicinal abortion services (EXCLUDING the medications): S0199 = MEDICALLY INDUCED ABORTION BY ORAL INGESTION OF MEDICATION INCLUDING ALL ASSOCIATED SERVICES AND SUPPLIES (E.G., MEMBER COUNSELING, OFFICE VISITS, CONFIRMATION OF PREGNANCY BY HUMAN CHORIONIC GONADOTROPIN (hCG), ULTRASOUND TO CONFIRM DURATION OF PREGNANCY, ULTRASOUND TO CONFIRM COMPLETION OF ABORTION)
- e. S0199 covers:
 - i. Office visit #1
 - 1. Member check-in, counseling and consultation
 - 2. Confirmation of pregnancy and fetal gestational age (either by hCG or ultrasound)
 - ii. Office visit #2
 - 1. Member check-in and consultation
 - 2. Confirmation of pregnancy termination (either by hCG or ultrasound)
- f. Two billing methods and rates are identified for S0199:
 - i. S0199 (without any modifier): is billed when use of an ultrasound is **included** in the above noted services.
 - ii. S0199 (with Modifier 52): is billed when an ultrasound is NOT utilized as part of the above noted services.
- 2) Submission of a Department's Abortion Certification Statement Form is required with any abortion-related claim. Two forms are available: 1) for a life-endangering circumstance, and 2) for a Rape or Incest circumstance. For a medicinally-induced abortion, the rape/incest identified Abortion Certification Statement Form must be utilized. A fully completed and provider-signed Abortion Certification Statement Form is always required with any claims that include abortion-related services.

The <u>Certification Statement for Abortion to Save the Life of the Mother</u> and the <u>Certification Statement for</u> <u>Abortion for Sexual Assault (Rape) or Incest</u> forms are available on the <u>Provider Forms web page</u> under Claim Forms and Attachments > Women's Health drop-down sections.

Provider Billing Training Sessions

October and November 2019 Provider Billing Training Sessions

Providers are invited to participate in training sessions for an overview of Health First Colorado billing instructions and procedures. The current and following months' workshop calendars are shown below.

Who Should Attend?

Staff who submit claims, are new to billing Health First Colorado services, or need a billing refresher course should consider attending one or more of the following provider training sessions.

The UB-04 and CMS 1500 training sessions provide high-level overviews of claim submission, prior authorizations, navigating the <u>Department's website</u>, using the <u>Provider Web Portal</u>, and more. For a preview of the training materials used in these sessions, refer to the <u>UB-04 Beginning Billing Workshop</u> and <u>CMS 1500</u> <u>Beginning Billing Workshop</u>, available on the <u>Provider Training web page</u> under the Billing Training and Workshops drop-down section.



Specialty training sessions provide more training for that particular provider specialty group. Providers are advised to attend a UB-04 or CMS 1500 training session prior to attending a specialty training. For a preview of the training materials used for specialty sessions, visit the <u>Provider Training web page</u> and open the Billing Training and Workshops drop-down section.

For more training materials on navigating the Provider Web Portal, refer to the Provider Web Portal Quick Guides available on the <u>Quick Guides and Webinars web page</u>.

Note: Trainings may end prior to 11:30 a.m. MT. Time has been allotted for questions at the end of each session.

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17 <u>CMS 1500</u> <u>Provider</u> <u>Workshop</u> 9:00 a.m 11:30 a.m. MT	18	19
20	21	22	23	24 <u>Provider</u> <u>Workshop</u> 9:00 a.m 11:30 a.m. MT	25	26

October 2019

Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
					1	2
3	4	5	6	7 <u>CMS 1500</u> <u>Provider</u> <u>Workshop</u> 9:00 a.m 11:30 a.m. MT	8	9
10	11	12	13	14	15	16
17	18	19	20	21 <u>UB-04</u> <u>Provider</u> <u>Workshop</u> 9:00 a.m 11:30 a.m. MT	22	23

November 2019

Live Webinar Registration

Register for a live webinar by clicking the title of the desired training session in the calendar above and completing the webinar registration form. An automated response will confirm the reservation. Do **not** register via these links if planning to attend a training session in person at the DXC office (see instructions below for RSVPing to attend in person).

For questions or issues regarding webinar registration, email <u>co.training@dxc.com</u> with the subject line "Webinar Help." Include a description of the issue being experienced, name and contact information (email address and phone number), and the name and date of the webinar(s) to be attended. Allow up to 2-3 business days to receive a response.

In-Person Training Registration

Providers who would like to attend a training session **in person** should RSVP to <u>co.training@dxc.com</u> by noon the day prior to the training, with the subject line "In-Person RSVP." Please include attendee name(s), organization, contact information (email address and phone number), and the name and date of the training session(s) to be attended. Allow up to 2-3 business days to receive a confirmation for in-person training reservations. Do not send an RSVP via email unless planning on attending **in person**.

In-person training sessions will be held at the following address:

DXC Technology Office Civic Center Plaza 1560 Broadway St, Suite 600 Denver, CO 80202

Parking and Transportation

Free parking is not provided, and parking is limited in the downtown Denver area. Commercial parking lots are available throughout the downtown area. The daily rates range between \$5 and \$20. Carpooling and

early arrival are recommended to secure parking. Whenever possible, public transportation is also recommended. Some forms of public transportation include the <u>Light Rail</u> and <u>Free MallRide</u>.

Upcoming Holidays

Holiday	Closed Offices/Offices Open for Business
Columbus Day - Monday, October 14, 2019	State Offices and the ColoradoPAR Program will be closed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks. DXC and DentaQuest will be open.
Veterans Day Monday, November 11, 2019	State Offices and the ColoradoPAR Program will be closed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks. DXC and DentaQuest will be open.
Thanksgiving Day Thursday, November 28, 2019	State Offices, DentaQuest, DXC and the ColoradoPAR Program will be closed. The receipt of warrants and EFTs may potentially be delayed due to the processing at the United State Postal Service or providers' individual banks.

DXC Contacts

DXC Office

Civic Center Plaza 1560 Broadway St, Suite 600 Denver, CO 80202

Provider Services Call Center 1-844-235-2387

DXC Mailing Address

P.O. Box 30 Denver, CO 80201